Greenwich LifeSciences to Present at the Annual LD Micro Main Event
December 02 2020 - 7:00AM
Business Wire
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a
clinical-stage biopharmaceutical company focused on the development
of GP2, an immunotherapy to prevent breast cancer recurrences in
patients who have previously undergone surgery, today announced
that it will be presenting at the Annual LD Micro Main Event to be
held virtually from December 14-15, 2020.
Snehal Patel, CEO of Greenwich LifeSciences, will present and
then participate in a live Q&A session by a panel of investors.
The presentation will be held at 1:20 pm EST on December 15, 2020,
and will highlight the Company’s recently published GP2 data and
its plans to commence a Phase III clinical trial. The corporate
presentation is currently available on the investor section of the
Company’s website at:
https://investor.greenwichlifesciences.com/
About LD Micro
LD Micro is the host of the most influential conferences in the
small-cap world. LD Micro was founded in 2006 with the sole purpose
of being an independent resource in the microcap space. What
started out as a newsletter highlighting unique companies has
transformed into several influential events annually (Invitational,
Summit, and Main Event). With the recent SRAX acquisition, LD has
access to the largest active base of micro-cap investors in the
world at over 2 million and counting. For more information, please
visit the conference website at: https://ve.mysequire.com/
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over
her lifetime, with approximately 266,000 new breast cancer patients
and 3.1 million breast cancer survivors in 2018. HER2/neu (human
epidermal growth factor receptor 2) protein is a cell surface
receptor protein that is expressed in a variety of common cancers,
including in 75% of breast cancers at low (1+), intermediate (2+),
and high (3+ or over-expressor) levels.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical
company focused on the development of GP2, an immunotherapy to
prevent breast cancer recurrences in patients who have previously
undergone surgery. GP2 is a 9 amino acid transmembrane peptide of
the HER2/neu protein. In a randomized, single-blinded,
placebo-controlled, multi-center (16 sites led by MD Anderson
Cancer Center) Phase IIb clinical trial, no recurrences were
observed in the HER2/neu 3+ adjuvant setting after median 5 years
of follow-up, if the patient received the 6 primary intradermal
injections over the first 6 months (p = 0.0338). Of the 138
patients that have been treated with GP2 to date over 4 clinical
trials, GP2 treatment was well tolerated and no serious adverse
events were observed related to GP2 immunotherapy. Greenwich
LifeSciences is planning to commence a Phase III clinical trial
using a similar treatment regime as the Phase IIb clinical trial.
For more information on Greenwich LifeSciences, please visit the
company’s website: www.greenwichlifesciences.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201202005372/en/
Company Contact Snehal Patel Investor Relations (832)
819-3232 info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich
LifeSciences Dave Gentry RedChip Companies Inc. Office:
1-800-RED CHIP (733 2447) Cell: (407) 491-4498 dave@redchip.com
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024